Domestic bonds: AMAG Pharmaceuticals, 2.5% 15feb2019, USD (Conv.) (US00163UAA43)

Name: Domestic bonds: AMAG Pharmaceuticals, 2.5% 15feb2019, USD (Conv.) (US00163UAA43)
Creator: Cbonds
License: https://creativecommons.org/licenses/by/4.0/

Download

Copy issue information to clipboard

Copy to clipboard

Data copied to the clipboard

PDF download

Choose all Reset all

Download Cancel

Convertible

Status

Matured

Amount

175,000,000 USD

Placement

***

Redemption (put/call option)

*** (-)

ACI on

Country of risk

USA

Current coupon

Price

Yield / Duration

Calculate in two clicks! yield, duration and other parameters

Calculator

What is a calculator?

Placement amount

175,000,000 USD
Face value

1,000 USD
ISIN

US00163UAA43
CFI

DCFNGR
FIGI

BBG005ZPNFF9
Ticker

AMAG 2.5 02/15/19

explore the most comprehensive database

800 000

bonds globally

Over 400

pricing sources

80 000

stocks

9 000

ETF

track your portfolio in the most efficient way

Bond Search

Watchlist

Excel ADD-IN

Get access

— Are you looking for the complete & verified bond data?

— We have everything you need:

full data on over 700 000 bonds, stocks & ETFs; powerful bond screener; over 350 pricing sources among stock exchanges & OTC market; ratings & financial reports; user-friendly interface; available anywhere via Website, Excel Add-in and Mobile app.

Why

You will have detailed descriptive & pricing data for 650K bonds, 76K stocks, 8K ETFs

Get full access to the platform from any device & via Cbonds app

Enhance your portfolio management with Cbonds Excel Add-in

Build yield maps, make chart comparison within a click

Don't wait any longer — start using Cbonds today! Register

Files

Prospectus

Prospectus

Authorization required

It is only possible to download bond prospectuses for paid Premium subscription access

Trading chart

Stock exchange selection

More about Cbonds Estimation

Bond is not traded; the issue is redeemed

Data display in a chart | table

Work with the chart: switching the price, period, issue comparison

Customize fields in the table

Found:

Show all fields

from

ADD-IN
Cbonds add-in API
bond data api

Authorization required

You need to request access

* Data is not available within the selected subscription

Quotes from market participants are indicative

Stock exchange and OTC quotes

Quotes provided by information providers are indicative in nature

Issue information

Profile

AMAG Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of a therapeutic iron compound to treat iron deficiency anemia (IDA). The Company markets and sells Feraheme in the United States through its own commercial organization. Feraheme is approved for use in the treatment of both dialysis and non-dialysis dependent chronic kidney disease (CKD) patients. The Company’s principal source of revenue is from the sale of Feraheme (ferumoxytol) Injection for intravenous (IV). In December 2011, Feraheme was also granted marketing approval in Canada for use as an IV iron replacement therapy for the treatment of IDA in adult patients with CKD. GastroMARK, which is marketed and sold under the trade name Lumirem outside of the United States, is the Company’s oral contrast agent used for delineating the bowel in magnetic resonance imaging (MRI), and is approved and marketed in the United States, Europe, and other countries through its licensees.

Show more Hide

Issuer

Go to the issuer page
AMAG Pharmaceuticals
Full borrower / issuer name

AMAG Pharmaceuticals
Sector

Corporate
Industry

Pharmaceutical Preparation and Biotechnology

Volume

Placement amount

175,000,000 USD

Face value

Face value

1,000 USD
Outstanding face value

*** USD
Increment

*** USD

Cash flow parameters

Reference rate

***

Coupon Rate

***

Day count convention

***

Interest Accrual Date

***

Coupon frequency

*** time(s) per year
Payment currency

***
Maturity date

***

Cash flow

Export to Excel

Early redemption terms

***

explore the most comprehensive database

800 000

bonds globally

Over 400

pricing sources

80 000

stocks

9 000

ETF

track your portfolio in the most efficient way

Bond Search

Watchlist

Excel ADD-IN

Get access

— Are you looking for the complete & verified bond data?

— We have everything you need:

Why

You will have detailed descriptive & pricing data for 650K bonds, 76K stocks, 8K ETFs

Get full access to the platform from any device & via Cbonds app

Enhance your portfolio management with Cbonds Excel Add-in

Build yield maps, make chart comparison within a click

Don't wait any longer — start using Cbonds today! Register

Placement

Placement method

Open subscription
Placement type

Public
Placement

*** - ***
Initial issue price (yield)

(***%)
Geographic breakdown

***
Investor breakdown

***
The purpose of placing

The Issuer estimates that the proceeds from the Offering will be approximately $169.1 million (or approximately $193.3 million if the underwriters exercise their over-allotment option in full), after deducting fees and estimated expenses. In connection with the pricing of the Offering, the Issuer has entered into convertible note hedge transactions with one or more financial institutions (the “option counterparties”). The Issuer also has entered into warrant transactions with the option counterparties. The Issuer intends to use approximately $12.4 million of the net proceeds from the Offering (or $14.1 million of the net proceeds from the Offering if the Issuer sells additional warrants and enters into additional convertible note hedge transactions in connection with the full exercise of the underwriters’ over-allotment option) to pay the cost of the convertible note hedge transactions (after such cost is partially offset by the proceeds to the Issuer from the sale of the warrant transactions). The Issuer intends to use the remainder of the net proceeds from the Offering for working capital and other general corporate purposes, including to fund possible acquisitions of, or investments in, complementary businesses, products, services and technologies. The Issuer has not entered into any agreements or commitments with respect to any acquisitions or investments at this time.

Participants

Co-arranger

***, ***
Depository

***

Conversion and exchange

Initial premium

***%
Convertible until

***
Conversion terms

***

Additional information

Latest issues

Show all

News

17/10/2018	Moody's Investors Service withdrew LT- foreign currency credit rating for AMAG Pharmaceutical
01/10/2018	S&P Global Ratings withdrew Local Currency LT credit rating for AMAG Pharmaceutical
01/10/2018	S&P Global Ratings withdrew Foreign Currency LT credit rating for AMAG Pharmaceutical
01/02/2018	S&P Global Ratings downgrades Local Currency LT credit rating of AMAG Pharmaceutical to "B"; outlook stable
01/02/2018	S&P Global Ratings downgrades Foreign Currency LT credit rating of AMAG Pharmaceutical to "B"; outlook stable

All organization news

IFRS/US GAAP reports

2020
	I q eng
	II q eng
	III q eng

2019
	I q eng
	II q eng
	III q eng
	IV q eng
2018
	I q eng
	II q eng
	III q eng
	IV q eng
2017
	I q eng
	II q eng
	III q eng
	IV q eng
2016
	I q eng
	II q eng
	III q eng
	IV q eng
2015
	I q eng
	II q eng
	III q eng
	IV q eng
2014



	IV q eng

Show all Hide

Authorization required

You need to request access

Identifiers

ISIN

***
CUSIP

***
CUSIP 144A

***
CFI

DCFNGR
FIGI

BBG005ZPNFF9
WKN

A1ZDS1
Ticker

AMAG 2.5 02/15/19
Type of security by CBR

***

Bond classification

Rank: Undefined
Registered
Coupon bonds
Convertible
Amortization
Callable
CDO
Dual currency bonds
Variable rate
For qualified investors (CIS region)
Foreign bonds
Green bonds
Guaranteed
Inflation-linked principal
Supranational bond issues
Inflation-linked coupon
Mortgage bonds
Perpetual
Payment-in-kind
Non-Marketable Securities
Redemption Linked
Restructuring
Retail bonds
Covered
Securitization
Structured product
Commercial Bonds
Subordinated
Sukuk
Trace-eligible

Show more Hide

Restructuring

***